Effect of drug-to-lipid ratio on nanodisc-based tenofovir drug delivery to the brain for HIV-1 infection.
Effect of drug-to-lipid ratio on nanodisc-based tenofovir drug delivery to the brain for HIV-1 infection.
复制标题
DOI：
10.2217/nnm-2022-0043
复制
发表时间：
2022-06
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
联合抗逆转录病毒疗法显著推进了HIV-1感染的治疗。然而，HIV-1病毒仍然在大脑中持续存在；血脑屏障的不可达性允许持续的HIV-1感染和神经炎症。以纳米技术为基础的药物载体，如纳米盘状双胞体，可以提供一种解决方案来应对这一挑战。这项研究调查了一种联合抗逆转录病毒治疗药物(替诺福韦)载药纳米盘在体外和体内脑内治疗HIV-1的安全性和缓释性。纳米盘将药物包裹在其内部疏水核心中，并在所需位置以受控释放模式释放有效载荷。这项研究还包括在体外和体内模型中对纳米盘制剂进行比较药代动力学分析。这项研究为HIV-1治疗开发提供了纳米盘的潜在应用。
Combination antiretroviral therapy has significantly advanced HIV-1 infection treatment. However, HIV-1 remains persistent in the brain; the inaccessibility of the blood–brain barrier allows for persistent HIV-1 infections and neuroinflammation. Nanotechnology-based drug carriers such as nanodiscoidal bicelles can provide a solution to combat this challenge. This study investigated the safety and extended release of a combination antiretroviral therapy drug (tenofovir)-loaded nanodiscs for HIV-1 treatment in the brain both in vitro and in vivo. The nanodiscs entrapped the drug in their interior hydrophobic core and released the payload at the desired location and in a controlled release pattern. The study also included a comparative pharmacokinetic analysis of nanodisc formulations in in vitro and in vivo models. The study provides potential applications of nanodiscs for HIV-1 therapy development.
在同时暴露于 HIV-1 和沙奎那韦后，人脑内皮细胞中 MDR1 介导的药物流出发生特异性增加。
影响因子：
3.7
作者：
Roy U;Bulot C;Honer zu Bentrup K;Mondal D
通讯作者：
Mondal D